SAN JOSE, Calif. , March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platform
Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data
Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology
Multiple patients substantially exceed expected survival at low dose levels; absence of dose- limiting toxicities supports escalation to doses up to 100x higher
SAN JOSE, Calif. , Feb. 2, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
Notice of Allowance marks first Mexican patent to be issued on Anixa Breast Cancer Vaccine
SAN JOSE, Calif. , Dec. 15, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose
SAN JOSE, Calif. , Dec. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...